A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry
Miao Xu(National Institutes of Health), Catherine Z. Chen(National Institutes of Health), Manisha Pradhan(National Institutes of Health), Joshua Zimmerberg(National Institutes of Health), Gary R. Whittaker(Cornell University), Wei Zheng(Liaoning Cancer Hospital & Institute), Zina Itkin(National Institutes of Health), Carleen Klumpp‐Thomas(National Institutes of Health), Kirill Gorshkov(National Center for Advancing Translational Sciences), Sam Michael(National Institutes of Health), Marco R. Straus(Cornell University), Min Shen(Kaili University), Jennifer D. Petersen(National Institutes of Health), Wei Zhu(Shanghai Tenth People's Hospital), Hui Guo(First Affiliated Hospital of Xi'an Jiaotong University), Misha Itkin(National Institutes of Health)
Cited by 26
Related Papers
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
|Science Translational Medicine|2019|259
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs
|Emerging Microbes & Infections|2014|242
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
|ACS Pharmacology & Translational Science|2020|225